AU2017307643B2 - Cannabis Composition - Google Patents

Cannabis Composition Download PDF

Info

Publication number
AU2017307643B2
AU2017307643B2 AU2017307643A AU2017307643A AU2017307643B2 AU 2017307643 B2 AU2017307643 B2 AU 2017307643B2 AU 2017307643 A AU2017307643 A AU 2017307643A AU 2017307643 A AU2017307643 A AU 2017307643A AU 2017307643 B2 AU2017307643 B2 AU 2017307643B2
Authority
AU
Australia
Prior art keywords
weight
amount
extract
cannabis
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017307643A
Other languages
English (en)
Other versions
AU2017307643A1 (en
Inventor
Mara GORDON
Harry KARELIS
Stewart Smith
Stewart WASHER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zelira Therapeutics Operations Pty Ltd
Original Assignee
Zelira Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61072172&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2017307643(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zelira Therapeutics Operations Pty Ltd filed Critical Zelira Therapeutics Operations Pty Ltd
Priority to AU2018100923A priority Critical patent/AU2018100923C4/en
Publication of AU2017307643A1 publication Critical patent/AU2017307643A1/en
Application granted granted Critical
Publication of AU2017307643B2 publication Critical patent/AU2017307643B2/en
Priority to AU2019253841A priority patent/AU2019253841B2/en
Priority to AU2021240297A priority patent/AU2021240297B2/en
Assigned to Zelira Therapeutics Operations Pty Ltd reassignment Zelira Therapeutics Operations Pty Ltd Request to Amend Deed and Register Assignors: Zelda Therapeutics Operations Pty Ltd
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2017307643A 2016-08-03 2017-08-03 Cannabis Composition Ceased AU2017307643B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2018100923A AU2018100923C4 (en) 2016-08-03 2018-07-03 Cannabis Composition
AU2019253841A AU2019253841B2 (en) 2016-08-03 2019-10-23 Cannabis Composition
AU2021240297A AU2021240297B2 (en) 2016-08-03 2021-10-01 Cannabis Composition

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662370304P 2016-08-03 2016-08-03
US62/370,304 2016-08-03
PCT/AU2017/050814 WO2018023163A1 (en) 2016-08-03 2017-08-03 Cannabis composition

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2018100923A Division AU2018100923C4 (en) 2016-08-03 2018-07-03 Cannabis Composition
AU2019253841A Division AU2019253841B2 (en) 2016-08-03 2019-10-23 Cannabis Composition

Publications (2)

Publication Number Publication Date
AU2017307643A1 AU2017307643A1 (en) 2018-07-05
AU2017307643B2 true AU2017307643B2 (en) 2019-07-25

Family

ID=61072172

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2017307643A Ceased AU2017307643B2 (en) 2016-08-03 2017-08-03 Cannabis Composition
AU2018100923A Expired AU2018100923C4 (en) 2016-08-03 2018-07-03 Cannabis Composition
AU2019253841A Ceased AU2019253841B2 (en) 2016-08-03 2019-10-23 Cannabis Composition
AU2021240297A Ceased AU2021240297B2 (en) 2016-08-03 2021-10-01 Cannabis Composition

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2018100923A Expired AU2018100923C4 (en) 2016-08-03 2018-07-03 Cannabis Composition
AU2019253841A Ceased AU2019253841B2 (en) 2016-08-03 2019-10-23 Cannabis Composition
AU2021240297A Ceased AU2021240297B2 (en) 2016-08-03 2021-10-01 Cannabis Composition

Country Status (15)

Country Link
US (2) US11779562B2 (https=)
EP (1) EP3493798A4 (https=)
JP (1) JP2019523283A (https=)
KR (2) KR20190035791A (https=)
CN (1) CN109843287A (https=)
AU (4) AU2017307643B2 (https=)
BR (1) BR112019001852A2 (https=)
CA (1) CA3031810A1 (https=)
CL (1) CL2019000270A1 (https=)
CO (1) CO2019001044A2 (https=)
IL (2) IL296008B2 (https=)
MX (1) MX386620B (https=)
PE (1) PE20200726A1 (https=)
SG (1) SG11201900665VA (https=)
WO (1) WO2018023163A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3031810A1 (en) 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
JP2019526541A (ja) 2016-08-03 2019-09-19 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 大麻組成物
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
NZ757591A (en) * 2017-03-30 2026-03-27 Ojai Energetics Pbc Methods and compositions for enhancing health
AU2018100837B4 (en) * 2017-06-19 2019-02-21 Zelira Therapeutics Operations Pty Ltd Sleep Disorder Compositions and Treatments Thereof
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
WO2019173242A1 (en) * 2018-03-04 2019-09-12 Cmg Partners, Inc. Enhanced smokable cannabis-based therapeutic product for treatment of sleep disorders and chronic pain and method for making same
US20210251949A1 (en) * 2018-06-15 2021-08-19 California Cannabinoids Compositions and Methods for Treatment of Narcolepsy and Related Disorders
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
US20220160648A1 (en) * 2019-02-13 2022-05-26 Inspired Health Products, LLC Composition Comprising Hydrolyzed Collagen and Cannabidiol and Use Thereof
NL2022616B1 (en) 2019-02-21 2020-09-18 Patrick Alexander Unger Cannabigerol and pharmaceutical compositions comprising cannabigerol for use in the treatment of insomnia
US11554098B2 (en) 2019-05-03 2023-01-17 HFL Partners, LLC Compositions comprising molecularly separated cannabinoids and terpene blends and methods of producing
CN118161552A (zh) * 2019-12-19 2024-06-11 史蒂文·罗斯斯坦 富含多酚化合物的提取物以及相关方法
US11000818B1 (en) * 2019-12-27 2021-05-11 Cresco Labs Llc Post processing method for cannabis oil
IT202000017137A1 (it) * 2020-07-15 2022-01-15 Linnea Sa Estratti di cannabis sativa e loro usi
DK181329B1 (en) * 2021-05-04 2023-08-16 Cs Medica As Nasal sleep spray composition, method for its provision, and receptacle and kit comprising said composition
US20230000935A1 (en) * 2021-07-03 2023-01-05 Joseph Anthony Bidwell Extract Infused Cannabis Flower, Natural preservation of Cannabis Flower and the method therefor
US20250144122A1 (en) * 2023-11-06 2025-05-08 Roberto Colon-Cruz Scent-Changing Ointment & Method of Making The Same
WO2026010279A1 (ko) * 2024-07-01 2026-01-08 피비엘바이오랩 주식회사 신규 유산균 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016030369A1 (en) * 2014-08-25 2016-03-03 Janing Holding Aps Device with compositions for delivery to the lungs, the oral mucosa and the brain

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2400319B (en) 2001-05-04 2005-06-08 Gw Pharma Ltd Cannabinoid-rich extracts
JP4411117B2 (ja) * 2004-03-25 2010-02-10 エスエス製薬株式会社 睡眠改善医薬組成物
GB2418612A (en) 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
JP2007246428A (ja) * 2006-03-15 2007-09-27 Nature Technology Inc 植物精油成分を有効成分とする経皮吸収型睡眠覚醒用医薬組成物、その組成物を含有する経皮吸収型睡眠覚醒用医薬製剤、及びこれらの製造方法
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
KR20110120153A (ko) * 2010-04-28 2011-11-03 고려대학교 산학협력단 리모넨을 함유하는 아데노신 Ａ2ａ 수용체 작용제
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2496688B (en) 2011-11-21 2016-06-29 Gw Pharma Ltd Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
AU2013257322A1 (en) 2012-05-03 2014-11-20 Echo Pharmaceuticals B.V. Cannabis plant isolate comprising delta9-tetrahydrocannabinol and a method for preparing such an isolate
US20150313868A1 (en) * 2012-12-18 2015-11-05 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
US10792318B2 (en) 2013-03-14 2020-10-06 Sc Laboratories, Inc. Bioactive concentrates and uses thereof
US9095554B2 (en) * 2013-03-15 2015-08-04 Biotech Institute LLC Breeding, production, processing and use of specialty cannabis
US10265292B2 (en) 2013-09-18 2019-04-23 The Werc Shop, LLC Terpene-based compositions, processes methodologies
LT3062606T (lt) * 2013-10-29 2019-07-10 Biotech Institute, Llc Specializuotų kanapių selekcija, gamyba, perdirbimas ir panaudojimas
CA2929280A1 (en) 2013-10-31 2015-05-14 Full Spectrum Laboratories, Ltd. Terpene and cannabinoid formulations
US10610512B2 (en) * 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use
AU2015279612A1 (en) 2014-06-27 2017-02-02 Kenton L. Crowley Buccal and sublingual cannabinoid formulations and method of making the same
CN107205960A (zh) 2014-10-21 2017-09-26 联合大麻公司 大麻提取物及其制备和使用方法
MX385464B (es) 2014-12-12 2025-03-18 Ojai Energetics Pbc Composiciones microencapsuladas de cannabinoides
IL253664B (en) 2015-01-31 2022-09-01 Constance Therapeutics Inc Production method for extracting oil from cannabis and preparations
BR112017018316A2 (pt) 2015-02-27 2018-04-17 Ebbu Llc composições compreendendo combinações de canabinoides purificados, com pelo menos um flavonoide, terpeno ou mineral
CA3031810A1 (en) 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
CA3031811A1 (en) 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
JP2019526541A (ja) 2016-08-03 2019-09-19 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 大麻組成物
AU2018100837B4 (en) 2017-06-19 2019-02-21 Zelira Therapeutics Operations Pty Ltd Sleep Disorder Compositions and Treatments Thereof
SG11202002169TA (en) 2017-09-15 2020-04-29 Zelda Therapeutics Operations Pty Ltd Composition and method for treating autism
AU2018100924A4 (en) 2018-07-03 2018-08-09 Zelira Therapeutics Operations Pty Ltd Composition and method for treating pain
WO2021248207A1 (en) 2020-06-12 2021-12-16 Zelira Therapeutics Operations Pty Ltd Composition and method for treating chronic pain
PE20240682A1 (es) 2020-11-06 2024-04-10 Zelira Therapeutics Operations Pty Ltd Tecnologia de encapsulacion de cannabinoides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016030369A1 (en) * 2014-08-25 2016-03-03 Janing Holding Aps Device with compositions for delivery to the lungs, the oral mucosa and the brain

Also Published As

Publication number Publication date
AU2019253841A1 (en) 2019-11-14
IL264461B1 (en) 2024-05-01
US12239628B2 (en) 2025-03-04
IL264461A (en) 2019-02-28
EP3493798A1 (en) 2019-06-12
US20220347155A1 (en) 2022-11-03
AU2018100923A4 (en) 2018-08-09
US20230414559A1 (en) 2023-12-28
IL296008B1 (en) 2024-05-01
CA3031810A1 (en) 2018-02-08
WO2018023163A1 (en) 2018-02-08
MX386620B (es) 2025-03-19
EP3493798A4 (en) 2020-05-06
CO2019001044A2 (es) 2019-04-30
SG11201900665VA (en) 2019-02-27
MX2019001285A (es) 2019-06-13
JP2019523283A (ja) 2019-08-22
AU2019253841B2 (en) 2021-07-01
IL264461B2 (en) 2024-09-01
BR112019001852A2 (pt) 2019-05-07
AU2018100923C4 (en) 2019-10-31
IL296008A (en) 2022-10-01
AU2017307643A1 (en) 2018-07-05
CL2019000270A1 (es) 2019-10-04
US11779562B2 (en) 2023-10-10
IL296008B2 (en) 2024-09-01
CN109843287A (zh) 2019-06-04
KR20190035791A (ko) 2019-04-03
AU2021240297A1 (en) 2021-10-28
AU2021240297B2 (en) 2023-08-24
AU2018100923B4 (en) 2018-09-27
PE20200726A1 (es) 2020-07-21
KR20210013645A (ko) 2021-02-04

Similar Documents

Publication Publication Date Title
US12239628B2 (en) Cannabis composition
US12239680B2 (en) Sleep disorder compositions and treatments thereof
US20220202767A1 (en) Cannabis composition
AU2018101357A4 (en) Composition and method for treating autism
US20210308092A1 (en) Cannabinoid composition and method for treating ptsd and/or anxiety
NZ789786A (en) Sleep Disorder Compositions and Treatments Thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: ZELIRA THERAPEUTICS OPERATIONS PTY LTD

Free format text: FORMER NAME(S): ZELDA THERAPEUTICS OPERATIONS PTY LTD

MK14 Patent ceased section 143(a) (annual fees not paid) or expired